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Abstract
Overexpression of the histone methyltransferase MMSET in t(4;14)+ multiple myeloma patients is believed to be the driving
factor in the pathogenesis of this subtype of myeloma. MMSET catalyzes dimethylation of lysine 36 on histone H3
(H3K36me2), and its overexpression causes a global increase in H3K36me2, redistributing this mark in a broad, elevated
level across the genome. Here, we demonstrate that an increased level of MMSET also induces a global reduction of lysine
27 trimethylation on histone H3 (H3K27me3). Despite the net decrease in H3K27 methylation, specific genomic loci exhibit
enhanced recruitment of the EZH2 histone methyltransferase and become hypermethylated on this residue. These effects
likely contribute to the myeloma phenotype since MMSET-overexpressing cells displayed increased sensitivity to EZH2
inhibition. Furthermore, we demonstrate that such MMSET-mediated epigenetic changes require a number of functional
domains within the protein, including PHD domains that mediate MMSET recruitment to chromatin. In vivo, targeting of
MMSET by an inducible shRNA reversed histone methylation changes and led to regression of established tumors in athymic
mice. Together, our work elucidates previously unrecognized interplay between MMSET and EZH2 in myeloma oncogenesis
and identifies domains to be considered when designing inhibitors of MMSET function.
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Introduction
Epigenetic control of gene expression plays a critical role in
many biological processes and aberrant chromatin regulation is
the driving factor in a multitude of diseases, including cancer.
Through studies of chromosomal rearrangements, copy number
changes, and more recently, sequencing of cancer genomes, it has
become apparent that genetic alterations of enzymes responsible
for covalent modification of histones or DNA, including histone
methyltransferases (HMTs), are a recurrent theme in the
pathogenesis of malignancy. Recently, HMTs have attracted
particular interest due to their potential as therapeutic targets [1],
but our understanding of the mechanisms by which abnormal
histone methylation leads to disease development is still incom-
plete.
The specificity of each HMT is encoded within the catalytic
SET (Suppressor of variegation, Enhancer of zeste and Trithorax)
domain. For example, trimethylation of lysine 27 on histone H3
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(H3K27me3) is mediated by the EZH2 protein, a member of the
Polycomb Repressive Complex 2 (PRC2) [2]. Binding of EZH2
and the presence of the H3K27me3 mark are found at
transcriptionally repressed loci and have been shown to play a
role in recruitment of additional transcriptional repressors,
including DNA methyltransferases (DNMTs) [3,4]. EZH2 gain-
of-function mutations that enhance H3K27me3 levels are
pathogenic for germinal center type large B cell lymphomas
[5,6], whereas global loss of EZH2 function due to mutation/
deletion of EZH2 or associated factors such as SUZ12, EED and
ASXL1 are associated with myeloid neoplasms [7–9].
MMSET (WHSC1/NSD2) is a histone methyltransferase whose
enzymatic specificity in vivo is towards dimethylation of lysine 36
on histone H3 (H3K36me2) [10–12], an epigenetic mark
associated with transcriptionally active loci [13]. Heterozygous
deletions of MMSET are implicated in the developmental disorder
Wolf-Hirschhorn syndrome (WHS), characterized by cognitive
and developmental defects [14]. Similar phenotypic defects are
observed in MMSET-deficient mice [15]. Alterations in MMSET
expression are also linked to cancer. This was first described in
multiple myeloma (MM), where ,20% of cases overexpress
MMSET due to the translocation t(4;14) [16], which places the
MMSET and FGFR3 loci under regulation of strong immuno-
globulin enhancers, leading to abnormally high levels of these
factors [17]. However, in 30% of cases, FGFR3 expression is not
affected, suggesting that misregulation of MMSET may be the
driving lesion of the disease [18,19]. A growing body of literature
demonstrates that increased expression of MMSET is associated
with advanced stage solid tumors, including prostate, bladder, lung
and skin cancers, where it may control oncogenic properties such
as the epithelial-mesenchymal transition [20–23]. Furthermore,
we recently identified a recurrent gain-of-function mutation of
MMSET (E1099K) most commonly found in lymphoid malig-
nancies, which enhances its methyltransferase activity and may
functionally mimic overexpression seen in other cancers [24,25].
The epigenetic alterations and biological consequences of
MMSET overexpression in cancer are beginning to be elucidated.
We and others showed that downregulation of MMSET
expression in t(4;14)+ cell lines leads to decreased proliferation
and loss of clonogenic potential [12,26]. In myeloma and prostate
cells, overexpression of MMSET causes a dramatic global increase
in H3K36me2, accompanied with a concomitant genome-wide
loss of H3K27me3 [12,20,27]. The change in histone methylation
is dependent on the HMT activity of MMSET and leads to altered
chromatin structure and aberrant gene expression [12].
In this work, we aimed to elucidate the mechanisms by which
MMSET alters gene expression in MM. Genome-wide chromatin
analysis showed that MMSET overexpression led to a widespread
redistribution in H3K36me2 across promoters, gene bodies and
intergenic regions, and gene activation correlated with removal of
the inhibitory H3K27me3 chromatin mark. Surprisingly, overex-
pression of MMSET induced transcriptional repression at specific
loci that became highly enriched for EZH2 and H3K27me3. This
increase was associated with augmented sensitivity to small
molecule inhibitors targeting EZH2 methyltransferase activity.
The ability of an epigenetic regulator to modify histones or DNA
depends on its ability to target specific loci through direct
interaction with chromatin, or through recruitment by other
transcriptional cofactors. We identified the domains of MMSET
that are required for its recruitment to chromatin and that are
necessary for methylation of H3K36 and loss of H3K27
methylation in t(4;14)+ cells. Both of these functions are necessary
for the oncogenic potential of MMSET. Lastly, we validated
MMSET as a therapeutic target by showing that loss of MMSET
expression in established t(4;14)+ tumors led to a decrease in
tumor burden and an increase in survival. Together, our results
reveal an interplay between H3K36 and H3K27 methylation in
t(4;14)+ myeloma and identify the domains of MMSET that could
be targeted in efforts to improve outcomes of this currently
incurable disease.
Results
MMSET alters the epigenetic landscape of t(4;14)+
myeloma cells
We and others have reported that the overexpression of
MMSET in t(4;14)+ myeloma cells increases global levels of
H3K36 dimethylation [11,12]. To investigate how the pattern of
H3K36me2 genomic distribution is affected by MMSET abun-
dance, we performed chromatin immunoprecipitation followed by
high-throughput sequencing (ChIP-seq) in TKO and NTKO cells
(two independent biological replicates for each sample). TKO is a
t(4;14)+ KMS11 cell line in which the rearranged IGH-MMSET
allele has been inactivated by homologous recombination. These
cells express only one wild-type copy of the MMSET gene at
physiological levels yielding low basal levels of H3K36me2
(Figure 1A) [26]. In their counterpart, NTKO cells, the wild-type
MMSET allele is inactivated, but high levels of MMSET and
H3K36me2 are maintained from the remaining rearranged IGH-
MMSET allele (Figure 1A). We performed microarray analysis in
NTKO and TKO cells to obtain global expression levels in these
cells. In agreement with previous studies [11], in MMSET-low
TKO cells, the presence of H3K36me2 positively correlated with
highly expressed genes (Figure 1B; Supplemental Figures S1A,
S1B). Typically, the enrichment of H3K36me2 peaked just
upstream of the transcription start site (TSS) and decreased
towards the 39 end of a gene (Figures 1B, 1C; Supplemental Figure
S1B). Our ChIP-seq analysis of NTKO cells revealed that this
characteristic distribution of H3K36me2 was disrupted in
MMSET-high conditions. Despite very high global levels of
Author Summary
Precise spatial and temporal gene expression is required
for normal development, and aberrant regulation of gene
expression is a common factor in many diseases, including
cancer. Histone modifications contribute to the control of
gene expression by altering chromatin structure and
affecting the recruitment of transcriptional regulators. In
this study, we demonstrate interplay between two
oncogenic proteins, MMSET and EZH2, known to methyl-
ate histone H3 on lysine 36 (H3K36) and lysine 27 (H3K27),
respectively. Overexpression of MMSET in myeloma cells
increases global levels of H3K36 methylation, alters its
normal distribution throughout the genome and decreas-
es global levels of H3K27 methylation. We found that while
the majority of the genome loses H3K27 methylation in
the presence of MMSET, certain loci have augmented
recruitment of EZH2 and enhanced H3K27 methylation,
leading to transcriptional repression. Repression of these
genes likely plays an important role in the disease because
MMSET-overexpressing cells show higher sensitivity to
small molecule inhibitors targeting EZH2-mediated meth-
ylation. Thus, our study suggests that the specific local
changes may outweigh the gross global changes we
frequently observe in cancer and implicates EZH2 as a
novel therapeutic target in myeloma cells.
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Figure 1. MMSET overexpression alters normal H3K36me2 distribution. (A) Loss of MMSET expression in t(4;14)+ cells depletes H3K36
methylation and increases H3K27 methylation. Immunoblot of nuclear extracts from t(4;14)+ KMS11 cells with inactivated translocated (TKO) or wild-
type (NTKO) MMSET allele were probed using antibodies for MMSET, H3K36me2, H3K27me3 and total H4 as control. (B) Heatmaps of H3K36me2
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H3K36 dimethylation in NTKO cells, H3K36me2 enrichment
did not localize to specific loci or domains (Figures 1B and 1C
intragenic). Instead, H3K36me2 enrichment was dispersed more
evenly throughout the genome and lacked clear boundaries
(Figure 1C intergenic, 1D bottom). In MMSET-high NTKO cells
characteristic peaks of H3K36me2 adjacent to the TSS were
eliminated and a lower uniform level of H3K36me2 was measured
throughout gene bodies (Figure 1C intragenic; Supplemental
Figure S1B). This decrease of intragenic H3K36me2 seemed
paradoxical as immunoblot and mass spectrometry clearly
demonstrated an approximately 8-fold increase of H3K36me2 in
NTKO cells (Figure 1A) [12,27]. This inconsistency was resolved
by examining H3K36me2 within intergenic regions, which
comprise 97% of the genome compared to the 3% of the genome
that is protein-coding [28]. Plotting the density of sequence tags
across 6,172 intergenic regions and comparing the relative
H3K36me2 enrichment revealed that MMSET-high NTKO cells
have an increase in abundance of the H3K36me2 modification
(Figure 1C). A large scale view over a gene-rich region illustrates
that peaks of H3K36me2 are obliterated in MMSET-high NTKO
cells (Figure 1D, top), whereas generally low levels of H3K36me2
in a gene-poor region are increased in the presence of high levels
of MMSET (Figure 1D, bottom; Supplemental Figure S1B). To
confirm that these findings were not due to the sequencing biases
that may occur due to dramatically different levels of H3K36me2
in the two cell types, we performed ChIP-qPCR analysis on three
loci, BTF3, SNX16 and GAPDH, whose expression does not
change in response to altered levels of MMSET. In MMSET-high
NTKO cells, H3K36me2 enrichment remains relatively constant
at the promoter or upstream of BTF3, SNX16 and GAPDH TSS
(Figure 1E, Supplemental Figures S2A and S2B). By contrast, in
MMSET-low TKO cells H3K36me2 peaks around the TSS and
then drops dramatically in regions away from the promoter
(Figure 1E, Supplemental Figures S2A and B). These data confirm
that the typical peaks of H3K36me2 enrichment at the transcrip-
tionally active loci are completely lost due to MMSET overex-
pression.
Despite the wide-ranging increase of H3K36me2 levels in
NTKO cells, we found that MMSET affects expression of only a
specific subset of genes. Gene expression profiling identified 522
genes upregulated with overexpression of MMSET and 308 genes
that are repressed in MMSET-high NTKO cells (Figure 2A;
Supplemental Table S1). To better understand the basis of
expression changes associated with MMSET abundance, we
examined the compiled H3K36me2 ChIP-seq profiles of genes
sorted based on their expression pattern in NTKO and TKO cells.
Specifically, regions upstream of the TSS of genes activated in the
presence of MMSET are more enriched for H3K36me2 in
NTKO than TKO cells (Figure 2B, red line and Supplemental
Figure S3A). These include adhesion molecules such as JAM2 and
JAM3 as well as CR2 (Figure 2C), the latter of which was shown
to play a role in the interaction of myeloma cells with the bone
marrow stroma [29]. However, within gene bodies of genes
activated by MMSET, the levels of H3K36me2 were very
comparable between NTKO and TKO cells (Figure 2B, red line).
This result suggested that the action of MMSET at the promoters
was important in regulation of these genes. Genes that were not
expressed in either NTKO or TKO cells did not have any
significant changes in the density of H3K36me2 (Figure 2B, light
blue line). However, genes repressed in the presence of MMSET
(Figure 2B, green line) or genes whose expression is not altered
due to MMSET (Figure 2B, dark blue line) seemed to be protected
from the global increase in H3K36me2 in NTKO cells and were
found to have higher levels of H3K36me2 in MMSET-low TKO
cells. We also performed ChIP-seq for trimethylated H3K36
(H3K36me3) in NTKO and TKO cells, a chromatin mark
enriched in gene bodies of highly expressed genes [30]. Although
global H3K36me3 distribution patterns were similar between
NTKO and TKO cells (Figure 2D; Supplemental Figure S3B), as
expected, the subset of genes upregulated in MMSET-high
NTKO cells exhibited elevated enrichment of H3K36me3
throughout their intragenic regions (Figure 2E). Similarly, genes
downregulated in the presence of high levels of MMSET, such as
DLL4, correlated with increased levels of H3K36me2 and
H3K36me3 in MMSET-low TKO cells (Figures 2C and 2E).
The relatively high number of repressed genes in NTKO cells
was unexpected given the global chromatin effects, increased
H3K36me2 and decreased H3K27me3, associated with MMSET
overexpression (Figure 1A). ChIP-seq analysis of H3K27me3 in
NTKO and TKO cells revealed that the upregulation of gene
expression in the presence of MMSET was accompanied by a loss
of H3K27me3, particularly in regions 59 to the TSS (Figures 3A,
red line, Figure 3B and Supplemental Figure S3A). Gene Set
Enrichment Analysis (GSEA) showed that the subset of genes
upregulated in MMSET-high NTKO cells represent direct targets
of EZH2 and H3K27 methylation (Figure 3C) [31–33]. This
suggests that MMSET itself or its resultant H3K36me2 modifi-
cation may prevent PRC2 binding to these loci, thereby inducing
gene expression by relief of active Polycomb repression. By
contrast, genes with expression levels that were unaffected by
MMSET abundance showed no significant difference in
H3K27me3 enrichment despite the global decrease of
H3K27me3 in NTKO cells (Figure 3A, dark blue). However,
genes repressed in the presence of high levels of MMSET or
transcriptionally silent in both cell types showed an increased
abundance of H3K27me3 in MMSET-high NTKO cells
(Figure 3A, green, light blue). On many genes repressed in the
presence of MMSET a large increase of H3K27me3 near the start
site of transcription was observed in NTKO cells (Figure 3D, 3E
and Supplemental Figures S4A and S4B). The HOXC cluster,
whose expression could not be detected in this cell system,
demonstrated fairly high levels of H3K27me3 dispersed across a
.60 kb genomic segment in MMSET-low TKO cells, that was
increased ,2.5-fold in MMSET-high NTKO cells (Figure 3F).
The chromatin landscape of genes exhibiting decreased expression
in MMSET-high cells was examined in TKO cells. Here, genes
distribution between NTKO (left) and TKO (right) cells. On the y-axis, genes were ranked based on their expression level from high (top) to low
(bottom) and on the x-axis, normalized read density from ChIP-seq experiments was plotted in gene bodies and 10 kb upstream and downstream
from the transcription start (TSS) and end (TES) sites. (C) MMSET alters H3K36me2 distribution in intragenic (top) and intergenic (bottom) regions.
(Top) Average read density across 15,386 genes in NTKO (left, red) and TKO (right, green) cells. (Middle) UCSC genome browser view of the H3K36me2
distribution on a representative locus (BTF3) in NTKO and TKO cells. (Bottom) Average normalized tag density of H3K36me2 in 6,172 intergenic
regions in NTKO (left) and TKO (right) cells. (D) Representative UCSC genome browser view of the H3K36me2 distribution on chromosome 8 of NTKO
(red) and TKO (green) cells. Top panel encompasses a gene-rich region of the chromosome and the bottom insert represents a 1MB region of the
8q24 gene desert. (E) ChIP-qPCR for H3K36me2 on the BTF3 locus. Methylation enrichment was tested 5 kb upstream of the TSS (59) and at the TSS
(right). Two independent biological replicates are shown.
doi:10.1371/journal.pgen.1004566.g001
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that were repressed in the presence of MMSET and activated in
TKO cells had increased levels of H3K36me2 and H3K36me3
and decreased levels of H3K27me3 (Figure 3G), and included
known EZH2/PRC2 targets, such as DLL4 and CDCA7
(Figure 3D) [32,34]. Thus, overexpression of MMSET not only
modifies H3K36me2 distribution, but also leads to a drastic
change in the distribution pattern of the repressive H3K27me3
mark. Whereas MMSET-overexpressing myeloma cells show a
Figure 2. High levels of MMSET lead to altered gene expression. (A) Dot plot representing differentially expressed genes in NTKO and TKO
cells from the microarray data. Genes upregulated and downregulated by MMSET (p,0.002) are in red (522 genes) and green (308 genes),
respectively; genes that do not change expression are in dark blue (10,884 genes) and genes that are not expressed (2,234 genes) in either cell line
are light blue. (B) Tag density profile of H3K36me2 distribution across different gene groups from A. Ratio between the number of reads in NTKO and
TKO cells is presented on the y-axis. (C) Quantitative RT-PCR validation of several genes upregulated and downregulated by MMSET overexpression.
(D) Heatmaps of H3K36me3 distribution between NTKO (left) and TKO (right) cells. Data were plotted as in Figure 1B. (E) Density tracks for H3K36me2
and H3K36me3 on a gene upregulated by MMSET (CR2 - upper panel) and a gene downregulated by MMSET overexpression (DLL4 – lower panel).
H3K36me2 tracks are in red and green for NTKO and TKO cells, respectively; H3K36me3 tracks are in blue (NTKO) and fuchsia (TKO).
doi:10.1371/journal.pgen.1004566.g002
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genome-wide decrease in H3K27me3, specific loci are able to
maintain and even gain higher levels of H3K27 methylation in the
presence of MMSET, leading to transcriptional repression.
MMSET overexpression alters patterns of EZH2 binding
Our previous work demonstrated that the epigenetic landscape
in t(4;14)+ cells is established by a competition between the
methylation activities of EZH2 and MMSET for the histone H3
tail substrate [27]. Furthermore, active chromatin marks, includ-
ing H3K36me2, were shown to inhibit PRC2 from both binding
the nucleosomes and methylating the histones [35,36]. Kinetic
studies revealed that once histone H3 reaches the dimethylation
state at H3K36, the effective rates of H3K27 di- and trimethyla-
tion on the same histone molecule drop dramatically [27].
Furthermore, we showed that MMSET-high cells have increased
rates of H3K27 demethylation contributing to the global loss of
this modification [27]. These data suggest that the global decrease
of H3K27 methylation in the presence of MMSET may be due to
the inability of EZH2 and the PRC2 complex to bind chromatin.
If this is true, then an increased concentration of unbound EZH2
would be available to bind genomic regions that are able to
maintain H3K27me3 in the presence of high levels of MMSET.
Therefore, this increased ratio of free enzyme to available
substrate could be responsible for the enhanced enrichment of
H3K27 trimethylation at specific loci in NTKO cells.
To test this hypothesis, we examined EZH2 distribution in
TKO and NTKO cells by ChIP-seq (two highly correlated
independent biological replicates, r = 0.82 and r = 0.84, respec-
tively) (Supplemental Figure S5A). This analysis identified 10,581
EZH2 peaks (associated with the promoters of 1,697 genes) in the
MMSET-high NTKO cells and 5,516 (953 genes) in the TKO
cells (Figure 4A and Supplemental Table S2). Of these genes, 733
were common between the two cell types and 964 genes had
enriched EZH2 binding exclusively in the NTKO cells. As
predicted, EZH2 peaks that are shared between NTKO and
TKO cells are on average higher and broader in NTKO cells
(Supplemental Figure S5B). In MMSET-high cells, enhanced
localization of EZH2 closely tracked with H3K27me3 enrich-
ment (Figure 4B), including DLL4 and CDCA7 promoters
(Figure 4C). Analysis of genes bound by EZH2 only in
MMSET-high NTKO cells, using a library of lymphoid biology
gene expression signatures [37], showed that they included genes
known to play a role in normal germinal center B cells
(GC_B_cell category), as well as known B cell MYC targets
(Myc_ChIP category) (Figure 4D and Supplemental Table S3).
Thus, aberrant EZH2-mediated repression of genes known to
play a role in lymphoid biology may be important for MMSET-
induced oncogenesis. Loci bound by EZH2 only in TKO cells
were enriched for genes found to be upregulated in t(4;14)+
patient samples (Figure 4D, Myeloma_MS category), suggesting
that MMSET overexpression reverses normal silencing of these
genes by the PRC2 complex.
Considering that many EZH2 bound regions were unique to
either MMSET-high or MMSET-low cells, we examined the
underlying sequence to determine if specific transcription factor
motifs were over-represented within these regions. This analysis
revealed that regions bound by EZH2 exclusively in MMSET-low
TKO cells coincided with GATA3, HOXA2 and PDX1 motifs
(Figure 4E). In breast cancer cells, GATA3 and EZH2 are
functionally antagonistic, suggesting that similar interplay between
these two factors may also exist in myeloma [38]. Interestingly,
EZH2-bound regions specific to MMSET-high NTKO cells were
associated with DNA motifs that resemble known CTCF DNA
binding sites (Figure 4E), implying a possible mechanism where
insulator sequences may protect these loci from methylation by
MMSET. Additional DNA motifs included poly-G and poly-C-
rich sequences (Supplemental Figure S5C), resembling PRC2
recruitment motifs defined in ES cells [39]. To determine whether
the enhanced binding of EZH2 may play a functional role in
myeloma cell survival, we treated MMSET-high and MMSET-
low cells with recently described small molecule inhibitor of EZH2
[40]. Indeed, MMSET-high cells were more sensitive to EZH2
inhibition (Figures 4F; Supplemental Figures S5D and S6A),
suggesting that some of the newly acquired EZH2 binding sites in
MMSET-high cells are critical for survival of these cells.
Translocations of c-MYC are common in multiple myeloma
and the MYC activation signature is observed in a majority of
MM patient samples [41,42]. Our previous study implicated
MMSET overexpression in the regulation of MYC through
downregulation of a microRNA, miR-126* [43]. In MMSET-
overexpressing cells expression of miR-126* levels is decreased
through recruitment of transcriptional repressors such as KAP1.
Our ChIP-seq analysis shows that MMSET overexpression leads
to EZH2 and H3K27me3 accumulation upstream of the
miR-126* locus (Supplemental Figure S6B). Upon treatment
with EZH2 inhibitors, MMSET-overexpressing cells increase
expression of miR-126* (Figure 4G). In accordance with our
previous study, increased miR-126* levels were associated with a
dramatic downregulation of MYC (Figure 4H). By contrast,
EZH2i had no effect on MYC levels in inhibitor-insensitive TKO
cells (Figure 4H). As myeloma cells are frequently dependent on
MYC for cell growth, the reduction in MYC levels in response to
EZH2i likely contributes to observed decrease in proliferation of
MMSET-overexpressing cells. To investigate other potential
mechanisms EZH2 sensitivity of MMSET-overexpressing cells,
we performed RNA-seq analysis in KMS11 and TKO cells
treated for seven days. In accordance with its role in gene
repression, inhibition of EZH2 primarily lead to activation of
gene transcription: 561 genes were upregulated in MMSET-high
cells and 1412 genes were activated in the TKO cells
(Supplemental Table S4). However, only 165 genes were
upregulated in both cell types further strengthening the idea that
EZH2 regulates expression of different loci in the presence or
absence of MMSET. Genes upregulated in MMSET-overex-
pressing cells include tumor suppressor DACH1 and members of
the WNT signaling pathway, however the role of these genes in
suppression of proliferation remains to be elucidated. Interest-
ingly, EZH2 inhibition in the TKO cells activated a number of
genes identified to be upregulated in t(4;14)+ myeloma patients
(Myeloma_MS_subgroup_up) suggesting that loss of H3K27
methylation, through MMSET overexpression or EZH2i, can
activate similar gene sets (Supplemental Figure S6C; Supple-
mental Table S5). This supports our notion that MMSET
activates expression by preventing EZH2 activity at specific loci
due to the mutually opposing interplay of H3K36 and H3K27
methylation. Together, we conclude that MMSET overexpres-
sion alters the genomic organization of EZH2 across the
myeloma genome and this effect, similar to other cancers,
induces misregulation of specific Polycomb target genes that
contribute to pathogenesis.
Oncogenic MMSET function depends on its PHD and
PWWP domains
In addition to the enzymatically active SET domain, MMSET
possesses four PHD domains commonly implicated in chromatin
binding [44]. To determine whether these and other conserved
domains of MMSET are required for myelomagenesis, we
repleted TKO cells with either wild-type MMSET or deletion
MMSET Reprograms Myeloma Epigenome
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Figure 3. MMSET alters genome-wide patterns of H3K27me3 methylation. (A) Tag density profile of H3K27me3 distribution across different
gene groups from Figure 2A. The ratio between read numbers in NTKO and TKO cells is presented on the y-axis. (B) UCSC genome browser display of
H3K27me3 density tracks surrounding the transcription start site of two MMSET activated genes, CA2 (top) and CR2 (bottom). (C) GSEA analysis of
genes upregulated by MMSET shows enrichment of previously identified EZH2 target genes. (D) UCSC genome browser display of H3K27me3 density
MMSET Reprograms Myeloma Epigenome
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mutants and assessed for changes in chromatin modifications, gene
expression and growth (Figure 5A). Expression of wild-type
MMSET in TKO cells re-established high levels of H3K36me2
and loss of H3K27me3 (Figure 5B), activated transcription of
specific genes, such as JAM2 (Figure 5C; Supplemental Figure
S7A), stimulated proliferation (Supplemental Figure S7B) and
increased colony formation (Figure 5D; Supplemental Figure
S7C). A point mutation at tyrosine 1118 (Y1118A) that abrogates
the HMT activity of MMSET [12] prevented the re-establishment
of H3K36 and H3K27 methylation in vivo (Figure 5B; Supple-
mental Figure S7D) and failed to stimulate gene expression
(Figure 5C), cell growth [12] and colony formation (Figure 5D;
Supplemental Figure S7C). A construct missing the C-terminal
portion of the protein, including PHD finger #4 (-PHD4), was
able to methylate H3K36, albeit at lower levels (Figure 5B) [27],
and resulted in an incomplete loss of H3K27 methylation
(Figure 5B), yielding an intermediate alteration of gene expression
(Figure 5C; Supplemental Figure S7A), growth stimulation (Sup-
plemental Figure S7B) and colony formation (Figure 5D and
Supplemental Figure S7B). These data suggest that the biological
contribution of MMSET in myeloma cells not only depends on its
ability to stimulate H3K36me2 levels, but also depends on the
degree of inhibition of H3K27 methylation.
MMSET also contains two PWWP domains, the first of which
has been suggested to nonspecifically bind chromatin [45].
However, in many MM cases, the t(4;14) breakpoint disrupts
MMSET 39 to the exons encoding PWWP1, leading to the
overexpression of a truncated MMSET lacking this domain. Thus,
while PWWP1 may play an important role for normal MMSET
function, it likely does not contribute to oncogenesis. However,
loss of the second PWWP domain rendered MMSET enzymat-
ically inactive (Figure 5B), and this construct (-PWWP2) was
unable to stimulate growth (Figure S5E), alter gene expression
(Figure 5C; Supplemental Figure S7A) or promote colony
formation (Figure 5D; Supplemental Figure S7C). Interestingly,
all deleted or mutated constructs were still able to bind chromatin
(Figure 5E). Nevertheless, both -PWWP2 and Y1118A mutants
were unable to mediate methylation of lysine H3K36 on the
JAM2 locus and thus are unable to induce gene expression
(Figure 5C; Supplemental Figure S7A). By contrast, -PHD4
expression led to H3K36 methylation but its inability to induce
complete demethylation of H3K27 allowed for only partial JAM2
activation (Figure 5C; Supplemental Figure S7A). We conclude
that the ability of MMSET to induce a complete H3K36/H3K27
methylation switch in myeloma cells depends on a complex
interplay of several domains of the protein. Furthermore, our data
suggest that both methylation of H3K36me2 and demethylation of
H3K27me3 are required for MMSET to fully alter gene
expression observed in myeloma.
MMSET binding to chromatin and methylation of
histones depends on specific PHD domains
We showed previously that the MMSET C-terminal isoform,
REIIBP, which contains the third and fourth PHD fingers, the
second PWWP domain and the SET domain, is not able to
methylate histones in TKO cells [12]. We systematically added
back additional domains of MMSET to REIIBP and found that
addition of PHD finger 2 or PHD fingers 1 and 2 together
(Figure 6A) induced methylation of H3K36 and demethylation of
H3K27me3 (Figure 6B), as well as enhanced colony formation
(Supplemental Figure S8A). Mutations and deletions in NSD1, an
HMT closely related to MMSET, are implicated in Sotos
syndrome, a disorder characterized by developmental overgrowth
and cognitive disabilities [46]. We mapped previously identified
mutations in NSD1 from Sotos syndrome patient samples to
MMSET in attempt to identify important domains that are
required for proper function of the two proteins (Figure 6A).
Single point mutations of cysteine residues 720, 735 or 857, all
within the second or third PHD finger of MMSET, rendered
MMSET incapable of modulating H3K36 and H3K27 levels
(Figure 6C). Similar to the enzymatically-dead SET domain
mutant, expression of these PHD point mutants in TKO cells
failed to stimulate colony formation (Figure 6D; Supplemental
Figure S8B) or activate gene expression (Figure 6E). Importantly,
ChIP assays for MMSET in repleted TKO cells revealed that the
C720R and C857R mutant proteins exhibited dramatically
reduced binding to the JAM2 promoter, likely explaining their
failure to methylate histones (Figure 6F). These data suggest that
the PHD fingers of MMSET play an important role in recruitment
of the protein to chromatin. In addition, these findings suggest that
the Sotos syndrome mutations in NSD1 may have similar
consequences, rendering the enzyme incapable of regulating
chromatin structure and gene expression.
Targeting MMSET decreases tumor burden in NOD/SCID
mice
Elevated expression of MMSET in a number of different types
of cancer suggests that inhibiting MMSET may be therapeutically
advantageous beyond multiple myeloma. However, because
MMSET translocation in myeloma occurs early in the premalig-
nant MGUS (Monoclonal Gammopathy of Undetermined Signif-
icance) stage of the disease, it is unclear to what extent fully
developed tumors depend on MMSET expression or whether
targeting MMSET can lead to tumor reduction. To test whether
MMSET reduction can inhibit myeloma growth in vivo, we
injected the flanks of NOD/SCID mice with t(4;14)+ KMS11 cells
expressing a doxycycline-inducible shRNA targeting MMSET.
We previously demonstrated that expression of this shRNA
decreases MMSET and H3K36me2 levels, increases H3K27me3
levels and leads to cell growth arrest [12]. Expression of the
luciferin gene in the KMS11 cells allowed for in vivo live-cell
imaging to monitor disease development. Tumors were allowed to
grow for seven days, after which half of the mice were given
doxycycline (dox) in their water to induce shRNA expression. As a
result, all of the treated animals had dramatically reduced tumor
volumes and in some cases, complete regression (Figures 7A–C
and Supplemental Figure S9). By contrast, five weeks after
injection of tumor cells, all untreated animals required sacrifice
due to tumor progression. The reduction in tumor size in dox-
treated animals was accompanied with a global loss of H3K36
dimethylation and an increase in H3K27 trimethylation (Fig-
ure 7D). To determine whether this was a long-lasting effect, we
removed doxycycline after four weeks of treatment and observed
the animals for four additional weeks. Even in the absence of
tracks surrounding the transcription start site of two MMSET repressed genes, DLL4 (top) and CDCA7 (bottom). (E) ChIP-qPCR for H3K27me3 on CDCA7
locus. Methylation enrichment was tested on the promoter (TSS) and on the regions upstream (59) and downstream (39) from the TSS. Two
independent biological replicates are shown. (F) UCSC genome browser of H3K27me3 enrichment on non-expressed genes of the HOXC cluster (left)
and ChIP-qPCR for H3K27me3 on the HOXC10 locus (right). Two independent biological replicates are shown. (G) Tag density profile of H3K36me2
(left), H3K36me3 (middle) and H3K27me3 (right) distribution of differentially expressed genes in TKO cells.
doi:10.1371/journal.pgen.1004566.g003
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Figure 4. MMSET alters EZH2 binding in t(4;14)+ myeloma cells. (A) Venn diagram showing overlap of genes bound at their promoters by
EZH2 in NTKO (blue) and TKO (yellow) cells. (B) UCSC genome browser display of H3K27me3 (top, gray) and EZH2 binding (bottom, red) in NTKO cells.
(C) UCSC genome browser display of EZH2 ChIP-seq tracks in NTKO (top, red) and TKO (bottom, green) cells associated with MMSET-repressed genes,
CDCA7 (left) and DLL4 (right). (D) Heat map of over-represented gene categories among genes bound by EZH2 in either NTKO cells, TKO cells or both
cell types. Enrichment was measured using iPAGE analysis [74]. (E) Motif analysis using HOMER [73] identified conserved sequences bound by EZH2 in
NTKO cells, TKO cells or both cell types. (F) Relative cell number of MMSET-high and MMSET-low cells treated with indicated doses of the EZH2 small
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shRNA expression, some tumors continued to decrease in size
(Figure 7A). Animals whose tumors disappeared completely
remained tumor-free even in the absence of doxycycline.
However, tumors that persisted during induction of the MMSET
shRNA eventually started to grow back upon doxycycline
removal, albeit at a reduced rate. Thus, we conclude that
established t(4;14)+ tumors depend on MMSET expression for
their proliferation and that inhibition of MMSET function
represents a rational form of therapy targeting against cancers
that express high levels of this protein.
Discussion
MMSET is a global epigenetic regulator
Deregulation of epigenetic machinery is one of the main drivers
of oncogenic transformation and cancer development. While
alterations of many epigenetic regulators seem to affect a specific
subset of downstream gene targets and pathways, there is a
growing number of examples where deregulation of a single
component of the machinery affects the global epigenetic
landscape, including mutations in EZH2, TET2, ASXL1 and
SETD2, among others [5,7,8,47–49]. Besides affecting gene
regulation, epigenetic anomalies that change overall chromatin
structure might affect other chromatin-dependent processes such
as DNA repair and DNA replication.
In t(4;14)+ myeloma, overexpression of MMSET induces a
dramatic increase in H3K36 dimethylation throughout the
genome. Normally, the H3K36me2 mark is enriched in the 59
and 39 proximity of the TSS of highly expressed genes however,
the precise role of H3K36me2 in transcriptional regulation is still
poorly understood and requires further investigation. Increased
methylation levels in the presence of MMSET alter the
distribution of this mark, leading to a net decrease in many gene
bodies and a significant increase in intergenic regions, with the
result being an ,8-fold overall increase in H3K36me2 levels [27].
Due to dramatic differences in H3K36me2 levels between NTKO
and TKO cells, analysis of this type of sequencing data across
different conditions presents unique challenges. One possible issue
is that ChIP-seq data measures only fractional enrichment and
that read numbers do not reflect global levels of H3K36
methylation. We used ChIP-PCR to confirm the patterns of
H3K36me2 distribution observed in ChIP-seq analysis (Figur-
es 1E and Supplemental Figures S2A and S2B). These data clearly
demonstrate that changes in H3K36me2 distribution observed
with ChIP-seq analysis are not artifacts due to a fixed number of
reads. Additionally, because of the dramatic changes in
H3K36me2 between the NTKO and TKO conditions, it is
difficult to find a convincing normalization factor for the reads
count. Specifically, when we plotted log of the ratio of the level of
H3K27me3 or H3K36me3 in TKO versus NTKO cells,
methylation assorted in a normal distribution with most regions
showing no change and a equal number of regions showing an
increase or decrease in histone methylation (Supplemental Figure
S10). By contrast, when the same plot was done for H3K36me2, a
bimodal distribution was found with most regions showing a
change in H3K36me2 levels with a subset showing a large increase
and another set with a large decrease (Supplemental Figure S10).
This violates the assumption of most existing normalization
methods, which is that the majority of the genome should have
similar methylation levels, and makes choosing a normalization
factor to use across all loci difficult. For this reason, our analysis is
focused mostly on the relative differences of the NTKO/TKO
ratio across classes of genes differentially expressed in the two cell
lines (Figures 2B and 3A). These distinct patterns (Figures 2B and
3A) would not be affected regardless of the normalization factor
used.
Our data also show that the global increase in H3K36
methylation leads to a concomitant genome-wide decrease of
H3K27 methylation. This result is in agreement with previous in
vitro studies showing that activating histone marks, including
H3K36 methylation, antagonize H3K27 methylation through
prevention of PRC2 binding to chromatin [35]. Surprisingly, our
analysis of H3K27me3 patterns in the presence of high levels of
MMSET show that while most of the genome is hypomethylated
at this residue due to increased H3K36me2, specific loci, including
previously identified Polycomb targets, are hypermethylated on
lysine 27 through enhanced recruitment of EZH2. A study by
Kalushkova et al. showed that Polycomb targets are normally
silenced in multiple myeloma cells and our study identifies one
possible mechanism explaining how this may be achieved [50].
EZH2/PRC2 complexes are recruited to chromatin via
sequence-specific transcription factors [51], through the ability of
PRC2 component Jarid2 to bind to DNA [52] and through the
ability of the EZH2 accessory protein EED to recognize and bind
to the H3K27me3 mark [53]. High levels of MMSET in the
t(4;14)+ cells lead to an increased rate of H3K36 methylation,
precluding the action of EZH2 and removing potential chromatin
binding sites for the PRC2 complex. EZH2 and PRC2 component
levels do not change in MMSET-high NTKO cells and thus we
propose a model where the PRC2 complex in the nucleus is
displaced from many genomic sites (Figure 7E). However, certain
loci fail to become hypermethylated on H3K36me2 in MMSET-
high cells. Among those, some sites have modest levels of
H3K27me3 and EZH2 binding in MMSET-low cells that are
further enhanced in MMSET-high cells, while other loci only
accumulate appreciable levels of EZH2 and H3K27 in the
presence of high levels of MMSET. Many of the EZH2 peaks
enhanced and unique to MMSET-high cells sit on CTCF sites,
known insulators that block the spread of chromatin marks. We
propose that overexpression of MMSET in myeloma plays a role
in establishing chromatin boundaries leading to accumulation of
EZH2/H3K27me3 and gene repression on one side of the
insulator. Previous studies in Drosophila showed that genome-wide
binding of CTCF aligns with H3K27me3 domains [54] and a very
recent study suggests that Drosophila MMSET homologue,
dMes4, directly interacts with insulator-binding protein Beaf32
and regulates H3K27me3 spreading [55]. Additionally, our model
is in agreement with recent work from Gaydos et al. showing that
in C. elegans, H3K36 methylation by MMSET homologue MES-
4 antagonizes H3K27 methylation across autosomes and concen-
trates H3K27me3 on the X chromosome [56]. Loss of MES-4
expression allows for spreading of the H3K27me3 mark on
autosomes and concomitant loss of the mark on the X
chromosome. Our findings, as well as those by Gaydos et al.,
molecule inhibitor (GSK343). Inactive compound, GSK669, was used as a control. Graph represents four independent experiments +/2 standard
deviation. (G) Quantitative RT-PCR measurement of miR-126* expression in KMS11 cells treated with GSK669 or GSK 343. Graph represents average
expression from three independent experiments +/2 standard deviation (* p,0.05). (H) Representative immunoblot of nuclear extracts from MMSET-
high (KMS11) and MMSET-low (TKO) cells treated for seven days with 2 mM EZH2 inhibitor (GSK343) or inactive control (GSK669). This experiment was
performed in biological triplicate.
doi:10.1371/journal.pgen.1004566.g004
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Figure 5. The MMSET-induced epigenetic switch depends on multiple domains. (A) Diagram of the wild-type (amino acids 1–1365) and
deletion MMSET constructs used for repletion experiments. Star represents location of the Y1118A mutation. –PHD construct encompasses amino
acids 1–1209 and –PWWP2 construct is missing amino acids 877–995. (B) Representative immunoblot of nuclear extracts from repleted TKO cells was
probed with the indicated antibodies. At least two independent infections were performed for each construct. (C) Representative qRT-PCR for JAM2
in repleted TKO cells. Measurements were performed from multiple infections in at least duplicate and the graph represents average expression +/2
standard deviation. (D) Methylcellulose colony formation assay using repleted TKO cells. Experiment was performed in triplicate and at least six
different fields were counted. Graph represents average colony count +/2 standard deviation. (E) ChIP assay on the JAM2 promoter using repleted
TKO cell. Two independent biological replicates are shown.
doi:10.1371/journal.pgen.1004566.g005
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Figure 6. PHD fingers 2 and 3 are required for proper MMSET function. (A) Diagram of the MMSET constructs used. PHD2-M2 and PHD1-M2
constructs start at amino acid 712 and 657, respectively. Mutations in the PHD domains are indicated as stars above the full-length MMSET. (B)
Representative immunoblot on nuclear extracts from repleted TKO cells probed with the indicated antibodies. At least two independent infections
were performed for each construct. (C) Nuclear extracts from the TKO cells repleted with PHD mutants were immunoblotted with the indicated
antibodies. At least two independent infections were performed for each construct. (D) Colony formation with TKO cells repleted with mutated PHD
constructs. Experiment was performed in triplicate and at least six different fields were counted. Graph represents average colony count +/2
standard deviation. (E) Quantitative RT-PCR of MMSET target genes CR2 and JAM3 using RNA from repleted TKO cells. Experiment was performed in
duplicate and graph represents average gene expression +/2 standard deviation. (F) Mutations in the PHD fingers prevent MMSET binding to
chromatin. ChIP assay on the JAM2 promoter using repleted TKO cells. Two independent biological replicates are shown.
doi:10.1371/journal.pgen.1004566.g006
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Figure 7. Targeting MMSET in t(4;14)+ tumors prolongs survival. (A) Mouse xenograft model using t(4;14)+ KMS11 cells harboring a
luciferase gene and a doxycycline-inducible MMSET-specific shRNA. Animals that were not administered doxycycline (2Dox) are shown on the top
and animals that were given doxycycline are shown on the bottom (+Dox). Two representative animals are shown from each group (n = 5) at the
following timepoints: 2 weeks after treatment; 4 weeks after treatment; 2 weeks after release from Dox; and 4 weeks after release from Dox. –Dox
animals were sacrificed 26 days after treatment initiation due to tumor size. The same two animals are shown at each time points. (B) Kaplan-Meier
curve of the xenograft mouse experiment from A. (C) Measurement of the luciferin signal in treated (black) and untreated (red) mice over time. (D)
Immunoblot for H3K36me2 and H3K27me3 using nuclear extracts from tumors isolated from the untreated or doxycycline-treated mice (E) Proposed
model for explaining how MMSET overexpression alters the epigenetic landscape of myeloma cells. Methylation of H3K36 by MMSET induces a global
MMSET Reprograms Myeloma Epigenome
PLOS Genetics | www.plosgenetics.org 13 September 2014 | Volume 10 | Issue 9 | e1004566
argue that localization of the H3K27 methyl mark greatly depends
on the number of genomic loci that are accessible for PRC2
activity. Our identification of CG-rich DNA motifs at sites of
enhanced EZH2 enrichment in MMSET-high cells, similar to
those previously described to aid in recruitment of EZH2 to
chromatin [39], suggests that the underlying DNA sequence also
plays a role in specifying genes particularly responsive to EZH2
activity. Furthermore, CpG islands have been shown to recruit
KDM2A, an H3K36-specific demethylase, which may provide a
suitable, H3K36-demethylated chromatin template for PRC2
binding [57]. Recently, a recurrent mutation in the gene encoding
histone H3 isoform H3.3 was identified in pediatric glioblastoma
patients, which converts lysine 27 to methionine [58]. In addition
to a genome-wide decrease in H3K27 methylation, as in the case
of MMSET overexpression, the H3K27M mutation also induces
focal increases in EZH2 and H3K27 methylation and aberrant
gene repression. Thus, the mechanism suggested by our study may
be applicable to other malignancies characterized by disrupted
H3K27 methylation.
MMSET as a therapeutic target
Multiple studies indicate that high levels of MMSET are not
exclusive to t(4;14)+ myeloma. Overexpression of MMSET also
occurs in a number of solid tumors [20,21] and is correlated with
the stage and aggressiveness of the disease. In prostate cancer, the
upregulation of EZH2 in high grade and metastatic disease
represses miR-203, which targets MMSET, explaining, at least in
part, MMSET upregulation [59]. Perhaps due to the parallel
increase of MMSET and EZH2 in prostate and other tumors,
studies to date have not shown a net increase in H3K36 or
depression of H3K27me3 in advanced-stage cancers. Neverthe-
less, we showed that siRNA depletion of MMSET in metastatic
but not in non-transformed prostatic epithelial cells results in a
switch in H3K36/H3K27 methylation, suggesting that metastatic
cancer cells may have increased dependency on MMSET for
lysine 36 methylation [20]. Additionally, we recently showed that
in acute lymphoblastic leukemia, a recurrent mutation within the
SET domain of MMSET enhances its methyltransferase activity
and induces a global epigenetic change similar to what is observed
when MMSET is overexpressed [24].
We and others showed that the histone methyltransferase
activity of MMSET is key to its oncogenic potential [11,12].
However, the full ‘‘chromatin switch’’ driven by MMSET
overexpression also depends on the second PWWP domain and
the PHD fingers 2, 3 and 4 (Figures 5 and 6). Loss of the second
PWWP domain leads to recruitment to chromatin but failure to
methylate H3K36. This effect might be due to allosteric
interactions between functional domains or improper alignment
of the protein on the nucleosome or DNA. In support of this idea,
Li et al. showed that in vitro methylation activity of MMSET was
augmented by the addition of DNA to the reaction mixture or by
the use of nucleosomes as a substrate [10]. The loss of the fourth
PHD domain is particularly interesting, as this truncation yields an
intermediate biological phenotype with an incomplete loss of
H3K27 methylation despite a global increase in H3K36me2,
albeit to somewhat lower degree than that generated by the WT
protein. This region of MMSET was shown to have an affinity for
unmethylated histone H3 peptides in vitro, but its deletion, unlike
the deletion of the PWWP domain, did not completely block its
ability to methylate chromatin [60]. Instead, the resulting partial
switch in chromatin was associated with incomplete gene
activation and modest growth stimulation, highlighting the
importance of H3K27me3/EZH2 dysfunction in the biology of
MMSET. The enhanced rate of H3K27me3 demethylation we
observed in MMSET-high NTKO cells [27] suggests that
MMSET may affect the activity of H3K27me3 demethylases,
possibly through the PHD4 domain. Alternatively, the genome-
wide distribution or effects of MMSET on H3K36me2 may be
qualitatively different with the loss of a domain that helps attract
MMSET to chromatin.
NSD1, a close homologue of MMSET, is fused to the NUP98
locus in rare cases of acute myeloid leukemia creating the NUP98-
NSD1 fusion protein [61]. Interestingly, the ability of NUP98-
NSD1 to transform mouse bone marrow cells and to activate Hox
gene expression depends on the presence of the analogous fourth
PHD finger of the NSD1 moiety [62]. The other PHD domains of
MMSET are also critical for its oncogenic function. This was
demonstrated by engineering mutations into PHD fingers 2 and 3
analogous to those found in NSD1 in Sotos syndrome patients
[63]. These point mutations of MMSET failed to bind chromatin
and failed to alter chromatin methylation. Our findings indicate
that PHD domains are additional regions of MMSET that may be
considered as therapeutic targets and suggest how these point
mutations may inactivate NSD1 in Sotos syndrome.
The sequencing of the coding regions and genomes of a variety
of human tumors showed that mutations in the epigenetic
apparatus are among the most common class of alterations in
cancer [47,49,64], further stimulating interest in epigenetically
targeted therapies [1]. While germinal cell lymphoma is associated
with gain-of-function mutations of EZH2 [5], multiple myeloma
has not been linked directly to alterations in EZH2 function.
However, mutations/deletions in the H3K27me3 demethylase
UTX are observed in multiple myeloma patients [65]. While the
role of UTX mutations in myelomagenesis is still unclear, it likely
involves increases in H3K27 methylation and aberrant gene
repression. Thus, the focal increase of H3K27 methylation in the
presence of MMSET may have a similar effect as UTX mutations,
suggesting that EZH2 plays an important, and so far underap-
preciated, role in multiple myeloma. Prior work implicated EZH2
in myeloma cell proliferation and transformation [66], and our
data suggest that t(4;14)+ cells may be particularly sensitive to
inhibition of EZH2 (Figure 4F; Supplemental Figure S6A). This
may be due to the ability of EZH2i to decrease c-MYC levels in
MMSET-overexpressing cells. We previously showed that
MMSET increased c-MYC levels by repression of miR126*
[43]. Here we show that in MMSET high cells, EZH2 and
H3K27me3 accumulate at the miR126 locus. Accordingly, we
found that EZH2i stimulates expression of miR126*, which can
then directly repress c-MYC protein expression (Figures 4G and
4H).
MMSET is commonly misregulated in human cancers and
inhibition of MMSET activity may have therapeutic potential for
a diverse set of tumors. In tumorigenic prostate cells, MMSET
expression maintains the transformed phenotype by stimulating
cell growth, migration and invasion [20,59]. Inhibition of
MMSET function in MM cells by shRNA in established
xenografts led to tumor regression in association with reversal of
the chromatin changes. Therefore, we hypothesized that agents
that block the enzymatic activity of MMSET or its ability to
properly dock with chromatin could represent potential new
decrease of H3K27me3, leading to activation of gene expression (bottom). Additionally, an overabundance of K36 methylation alters genome-wide
EZH2 binding, inducing focal increases in H3K27 methylation and gene repression.
doi:10.1371/journal.pgen.1004566.g007
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therapies. Although inhibition of enzymatic activities of proteins
such as MMSET and EZH2 is a rational approach, recent success
in targeting chromatin-reading domains of BRD4 suggest that
inhibition of non-enzymatic domains should also be considered
[67]. Indeed, our data suggest that targeting the PHD fingers or
PWWP domain may be equally sufficient in preventing MMSET
from methylating histones and altering gene expression. Recently
identified inhibitors of EZH2 [68,69] and hopefully soon to be
identified inhibitors of MMSET will allow us to determine the
therapeutic effects of these targeted therapies on a number of
cancer subtypes, including patients with t(4;14) translocations.
Materials and Methods
Ethics statement
Animal experiments were approved and in strict compliance
with institutional guidelines established by Northwestern Univer-
sity Animal Care and Use Committee (ASP# 2011-1373).
Tissue culture
All cells were grown in RPMI 1640 (Invitrogen) supplemented
with 10% heat-inactivated FBS and 1% penicillin/streptomycin.
Protein extraction and immunoblotting
Nuclear proteins were extracted using the Nuclear Complex
Co-IP Kit (Active Motif). Proteins were electrophoretically
separated, blotted and detected using enhanced chemilumines-
cence. Primary antibodies used were: H3K36me2 (Millipore 07-
369), H3K27me3 (Millipore 07-449), MMSET [12], c-MYC
(Abcam ab32072), HDAC2 (Millipore 05-814) and pan-H4
(Abcam ab7311). The secondary antibody used was horseradish
peroxidase-conjugated donkey anti-rabbit IgG (GE Healthcare
Life Sciences).
Chromatin immunoprecipitation
ChIP experiments for histone modifications and MMSET were
performed as described previously [12] using antibodies for
H3K36me2 (Millipore, 07-369), H3K36me3 (Abcam, ab9050),
H3K27me3 (Millipore, 07-449), MMSET [12], and rabbit IgG
(Abcam, ab37415) as a negative control. Histone antibody
specificity was confirmed using a MODified Histone Peptide
Array (Active Motif), according to the manufacturer’s instructions.
ChIP-qPCR primers can be found in Supplemental Table S7.
JAM2 promoter primers were previously described [12]. EZH2
ChIP experiments (Cell Signaling, 5246s), were performed with
following modification- cells were resuspended in nuclei lysis buffer
(10 mM Tris pH 7.5, 10 mM NaCl, 0.2% NP-40, protease
inhibitors) for ten minutes, centrifuged, washed and resuspended
in SZAK RIPA buffer (150 mM NaCl, 1%v/v Nonidet P-40,
0.5% w/v deoxycholate, 0.1% w/v SDS, 50 mM Tris pH 8,
5 mM EDTA, 0.5 mM PMSF, protease inhibitors) for sonication.
Preparation of ChIP libraries and sequencing was performed by
the Epigenomics Core at Weill Cornell Medical College. 10 ng of
input and ChIP material was processed using the Illumina kit (IP-
102-1001). Libraries were loaded onto a HiSeq 2000 or GAIIX at
6 pM, and subjected to 50 or 36 sequencing cycles, respectively.
For histone modifications, data from the HiSeq 2000 is presented
in the main text and experimental repeats from GAIIAX
sequencing are presented in the supplemental figures. Both
EZH2 ChIP-seq experiments were sequenced on HiSeq 2000.
Microarray analysis
Six replicate samples of both NTKO and TKO cells were run
on an Illumina microarray (HumanWG-6_V3_0_R0_11282955_
A). Among the 48,804 probes on the gene expression array, 28,124
probes were selected for further analysis based on having at least
four positive expression values among the six replicates in both
NTKO and TKO samples. Based on the Illumina annotation file
(http://www.switchtoi.com/annotationfiles.ilmn), a final set of
15,386 protein-coding genes out of the 28,124 selected probes was
identified. For each gene, a two-sample t-test was applied to obtain
the p-value for significance of differential expression between
NTKO and TKO cells. If a gene’s expression level (in log scale)
was lower than 3 in both NTKO and TKO cells, it was considered
as a ‘‘not expressed’’ gene. A two-sample t-test was conducted for
each gene not classified as ‘‘not expressed’’. Genes detected as
differentially expressed (p,0.002) were defined up or down
modulated according to the sign of t-statistics. All other genes
were classified as ‘‘not changed’’ in expression. The GEO
accession number for the Illumina gene expression data is
GSE57863.
Histone ChIP-seq data analysis
For histone modifications, the single-end reads were mapped to
the human genome (hg19 version) with bowtie 1 (version 0.12.7)
by allowing a maximum of 3 mismatches. About 70% to 74% of
raw reads were uniquely mapped to the genome for each sample,
which were used in the subsequent analysis. Supplemental Table
S6 summarizes the count of uniquely mapped reads for each
sample. Several reads mapping to the same exact location were
considered amplification artifacts and were excluded from the
analysis. If there was more than one read mapped to the same
genomic location on the same strand, only one read was kept at
that location. Supplemental Table S6 shows the updated read
number in each sample after removing redundancy. To calculate
the read density, each read was extended to the 39 direction for a
distance that approximates the length of the parental DNA
fragment from which the short reads derived. To estimate the
average length of DNA fragments, we first calculated the cross-
correlation between the read frequency on the Watson and Crick
strands for each sample. The lag corresponding to the peak point
in the cross-correlation function was regarded as the average
length of DNA fragments. The read density at any genomic
location is defined as the number of extended DNA fragments that
cover this given location. To estimate the read count of DNA
fragments centered at each position, the 59 end of each uniquely
mapped read was shifted towards the 39 direction by half fragment
size (fragment size as estimated above). To analyze methylation
patterns across the genome and compare them between different
samples, the read count of each sample was normalized by the
average read frequency per base pair of the effective genome size
(which was approximately the mappable human genome size and
was set as 2.76109 bp) [70]. After this normalization, the
expectation of average read count at any position is 1, and the
exact count would show the relative enrichment level compared to
average. The average of normalized read counts across all
positions in a given genomic window was used as a measure of
methylation level within that region. To analyze methylation
patterns across the gene body, each gene body was divided evenly
into 50 bins regardless of the length of the gene. As such, all genes
were perfectly aligned at the TSS and TES. The immediate
upstream and downstream 10 k regions were also divided into 50
bins of 200 bp each. The average of normalized read count
(defined as above) was used in the comparison of NTKO and
TKO samples. To analyze the methylation pattern in the
intergenic regions, for each of the 15,386 genes identified from
the microarray analysis, if the closest upstream gene was at least
30 kb away from the TSS of the current gene, the intergenic
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region was selected. This resulted in a total of 6172 intergenic
regions. We further ignored the first and last 10 kb of each
intergenic region (as these regions are included in the gene plots)
and divided the remaining part of each intergenic region evenly
into 100 bins. The average of normalized read count per bin was
used to compare NTKO samples with TKO samples as described
above. The GEO accession number for the histone ChIP-seq data
is GSE57977.
EZH2 ChIP-seq peak detection
All samples were aligned to human genome (hg18) using BWA
(version 0.5.8, default parameters). Several reads mapping to the
same exact location were considered amplification artifacts and
were excluded from the analysis. Each ChIP-seq data set was
normalized to its corresponding input lane. ChIP-seq peak calling,
genomic annotation of peaks, target genes and comparison of
EZH2 peaks in TKO and NTKO cells were performed using
ChIPseeqer [71]. The default parameters were used for peak
detection (i.e., 2-fold difference between ChIP and INPUT signal,
and 10215 statistical significance of the detected peaks). False
discovery rates (FDR) for TKO samples were 0.08 and 0.02 for
run 1 and run 2, respectively. For NTKO samples, FDR was
0.008 for run 1 and 0.003 for run 2. For both NTKO and TKO
samples run 2 peaks were used for downstream analysis.
Transcription factor motif analysis was performed using FIRE
[72], included in ChIPseeqer, and HOMER [73]. Pathway
analysis was performed using iPAGE [74], included in ChIPsee-
qer. The GEO accession number for the EZH2 ChIP-seq data is
GSE57632.
Read density tracks
Single-end reads were aligned with bowtie 1 by allowing a
maximum of 3 mismatches. The read density tracks were made
using the HOMER tool (version 3.11 using default parame-
ters), where each sample was normalized into 10 million reads
[73].
RNA-seq
Total RNA from KMS11 or TKO cells treated with 2 mM of
GSK343 or GSK669 for seven days was sequenced on HiSeq
2000. RNA-seq samples were aligned to hg19 using the STAR
aligner (v2.3.0). For the calculation of FPKM values, cuffdiff was
used (v2.1.2) and the UCSC hg19 annotation from igenomes
(the latest annotation to use: http://cufflinks.cbcb.umd.edu/
igenomes.html). Pathway analysis was performed using iPAGE
[74]. The GEO accession number for the RNA-seq data is
GSE57478.
Gene Set Enrichment Analysis (GSEA)
GSEA 2.0 with default parameters was used to identify the
enrichment of previously defined signatures among genes
upregulated in TKO cells.
RNA extraction, cDNA synthesis, and qRT-PCR
RNA was extracted from cells using the RNeasy Plus Mini Kit
(Qiagen). cDNA was synthesized from total RNA using the iScript
cDNA Synthesis Kit (Bio-Rad). Quantitative RT-PCR was
performed using predesigned TaqMan assays (Applied Biosystems)
for JAM2 (Hs00221894_m1), JAM3 (Hs00230289_m1), DLL4
(Hs00184092_m1), CA2 (Hs00163869_m1), CR2 (Hs00153398_m1),
CDCA7 (Hs00230589_m1), LTB (Hs00242739_m1) and normalized
to a GAPDH (Hs99999905_m1) control. qRT-PCR was run on a
LightCycler 480II (Roche).
EZH2 inhibitor treatment
16105 cells were plated in the presence of 1 mM, 2 mM or 4 mM
of GSK343 or GSK669 as a control. After seven days, cells were
counted and proteins extracted for immunoblotting.
miRNA expression analysis
To determine miRNA expression levels, total RNA was isolated
using the miRNeasy Mini Kit (Qiagen). The miRCURY LNA
Universal RT microRNA PCR kit (Exiqon) was used for reverse
transcription and miRNA amplification. Expression was calculated
using the DDCT method and U6 was used as internal controls.
Primers for miR-126* (cat. 204584) and U6 (cat. 203907) were
purchased from Exiqon.
Cloning and site-directed mutagenesis
All of the MMSET constructs were cloned into the pRetroX-
DsRed vector (Clontech) except PHD1-M2 and PHD2-M2, which
were cloned into pRetroX-ZsGreen (Clontech). A nuclear
localization signal was inserted at the N-terminus of PHD1-M2
and PHD2-M2 constructs. Site-directed mutagenesis of PHD
fingers 2 and 3 was performed using QuickChange Lighting Site-
Directed Mutagenesis Kit (Stratagene) following the manufactur-
er’s recommendations.
Retroviral infection
For the repletion system, TKO cells were transduced with
retroviral vectors harboring MMSET or mutant isoforms. All
retroviruses were produced by transfection of amphotropic 293T
cells with appropriate plasmids and FuGENE 6 Transfection
reagent (Roche). After infection, cells were sorted by flow
cytometry using the DsRed protein marker and expanded in
culture for further studies.
Colony formation assay
26103 cells were grown in 1 mL of semisolid methylcellulose
medium (MethoCult H4100; StemCell Technologies Inc.) supple-
mented with complete medium and heat-inactivated FBS. Two
weeks later, colonies were counted in at least 6 random fields.
Cell growth
36104 cells were grown in a 6-well plate with 2 mL of complete
medium. Live cells were collected and counted at indicated days
using trypan blue dye.
Mouse xenograft model
Six-week-old female C57BL6 Nu/Nu mice were obtained from
The Jackson Laboratory and were acclimated for at least for 24 h
before tumor cell injection. A total of 56106 KMS11 cells
harboring an inducible MMSET shRNA were resuspended in
100 mL cold PBS and were mixed with 100 mL of CultreX
PathClear BME (3432-005-02, Trevigen). The mixture was
injected subcutaneously in the dorsal region next to both thighs.
One week after injection, mice were divided in two groups (n = 5
per group). The control group was administered regular water and
the treatment group was given doxycycline 2 mg/mL in water
containing 0.04 g/mL of sucrose. The water was changed every
other day to ensure delivery of a stable dose of doxycycline. Two
weeks after treatment initiation, images were acquired using IVISR
Spectrum (Caliper Life Sciences, Inc.). For imaging, firefly
Luciferin (150 mg/kg) (Gold Biotechnology) was injected intra-
peritoneally and images were taken 10–15 min later. Bioluminis-
cence was quantified using Living Images software (Caliper Life
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Sciences, Inc.). GraphPad Prism software was used for survival
analysis.
For protein extraction, tumor samples were immediately frozen
in liquid nitrogen and stored at 280uC. Frozen tumors were
mechanically homogenized using a biopulverizer (Biospec) chilled
at 280uC, and incubated in lysis buffer (10 mM Hepes ph 7.9,
10 mM KCl, 1.5 mM MgCl2, 0.5% NP40, 1 mM PMSF, 1 mM
DTT, proteinase inhibitors) on ice for 20 min. Upon centrifuga-
tion, the supernatant containing the cytoplasmic fraction was
discarded and nuclei were resuspended in lysis buffer containing
20 mM Hepes pH 7.9, 400 mM NaCl, 1.5 mM MgCl2, 0.2 mM
EDTA, 15% glycerol, 1 mM PMSF, 1 mM DTT and proteinase
inhibitors. Lysates were incubated at 4uC for 20 min on an orbital
rotator and further sonicated for 20 min using a Bioruptor
(Diagenode, Inc) (30 seconds on, 30 seconds off). The supernatant
containing nuclear proteins was analyzed by immunoblot.
Supporting Information
Figure S1 (A) Heatmaps of H3K36me2 distribution between
NTKO (left) and TKO (right) cells using replicate samples. Data
were plotted as in Figure 1B. (B) Average read density across
15,386 genes and 6,172 intergenic regions using ChIP-seq
replicate samples.
(TIF)
Figure S2 (A) ChIP-qPCR for H3K36me2 on GAPDH locus.
Methylation enrichment was tested on the promoter (TSS) and on
the regions upstream (59) and downstream (39) from the TSS. Two
independent biological replicates are shown. (B) ChIP-qPCR on
SNX16 locus. H3K36me2 (top) and H3K27me3 (bottom)
enrichment was tested on the promoter (TSS) and on the regions
upstream (59) and downstream (39) from the TSS. Two
independent biological replicates are shown.
(TIF)
Figure S3 (A) ChIP-qPCR on CR2 locus. H3K36me2 (top) and
H3K27me3 (bottom) enrichment was tested on the promoter
(TSS) and on the regions upstream (59) and downstream (39) from
the TSS. Two independent biological replicates are shown. (B)
Heatmaps of H3K36me3 distribution in ChIP-seq replicate
samples in NTKO (left) and TKO (right) cells. Data were plotted
as in Figure 1B.
(TIF)
Figure S4 (A) ChIP-qPCR for H3K36me2 on CDCA7 gene.
Methylation enrichment was tested on the promoter (TSS) and on
the regions upstream (59) and downstream (39) from the TSS. Two
independent biological replicates are shown. (B) ChIP-qPCR for
H3K36me2 (left) and H3K27me3 (right) on the promoter of
DLL4 gene. Two independent biological replicates are shown.
(TIF)
Figure S5 (A) Correlation plot of two independent EZH2 ChIP-
seq experiments in NTKO (left) and TKO (right) cells. (B) Box plot
representing average height (left) or average length (right) of EZH2
peaks common in both NTKO and TKO cells. Statistical
significance was determined using Welch Two Sample t-test (***
p,1e-6). (C) Motif analysis using FIRE [72] identified sequences
enriched in EZH2-bound peaks in NTKO cells. (D) Immunoblot
of nuclear extracts from KMS11 and TKO cells treated with
1 mM or 2 mM GSK343 for seven days. Inactive compound
GSK669 was used as a control.
(TIF)
Figure S6 (A) Relative cell number of MMSET-high (KMS28,
OPM2) and MMSET-low (Karpas 620, ARP1) myeloma cells
treated with indicated doses of the EZH2 small molecule inhibitor
(GSK343) for seven days. Inactive compound, GSK669, was used
as a control. The graph represents three independent experiments
+/2 standard deviation. (B) UCSC genome browser of
H3K27me3 and EZH2 enrichment on miR-126* locus (C) Heat
map of over-represented gene categories among genes differen-
tially expressed ($2-fold) in MMSET-high (KMS11) or MMSET-
low (TKO) cells upon seven days of GSK343 treatment.
Enrichment was measured using iPAGE analysis [74].
(TIF)
Figure S7 (A) Quantitative RT-PCR for CR2 using RNA from
the TKO repletion experiment. Experiment was performed in
duplicate and graph represents average gene expression +/2
standard deviation. (B) Growth curve of TKO cells repleted with
either empty vector, wild-type MMSET or MMSET lacking
PHD4. Experiment was performed in triplicate and graph
represents average cell growth +/2 standard deviation. (C)
Images of the colony forming assay using repleted TKO cells.
(D) Mass spectrometry analysis of H3K27 and H3K36 methyla-
tion from TKO cells expressing vector control, wild-type MMSET
or enzymatically inactive Y1118A mutant MMSET. Analysis was
performed as previously described [27]. (E) Growth curve of TKO
cells infected with vector control, wild-type MMSET or MMSET
lacking the second PWWP domain. Experiment was performed in
triplicate and graph represents average cell growth +/2 standard
deviation.
(TIF)
Figure S8 (A) Colony forming assay, using TKO cells repleted
with vector control, wild-type MMSET, PHD1-M2 or PHD2-M2
constructs. Experiment was performed in triplicate and at least six
different fields were counted. Graph represents average colony
count +/2 standard deviation. (B) Image of the colony assay using
TKO cells repleted with vector control, wild-type MMSET or
MMSET mutated at cysteines 720 or 857.
(TIF)
Figure S9 Xenograft mice after four weeks of treatment. Three
mice on the left were untreated while the three mice on the right
received doxycycline in their drinking water.
(TIF)
Figure S10 Log2ratio plot of H3K27me3, H3K36me3 and
H3K36me2 methylation in NTKO and TKO cells. Normaliza-
tion factors were calculated using EdgeR with default parameters.
(TIF)
Table S1 Differentially expressed genes in NTKO and TKO cells.
(TXT)
Table S2 List of genes bound by EZH2 in NTKO cells only,
TKO cells only or bound in both cell types.
(TXT)
Table S3 Over-represented gene categories among genes bound
by EZH2 in NTKO and TKO cells.
(TXT)
Table S4 List of differentially expressed genes ($2-fold) upon
EZH2 inhibition in KMS11 and TKO cells.
(TXT)
Table S5 Over-represented gene categories among differentially
expressed genes ($2-fold) upon EZH2 inhibition in KMS11 and
TKO cells.
(TXT)
Table S6 Numbers of ChIP-seq reads.
(DOCX)
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Table S7 Primer sequences.
(TXT)
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